Infectious diseases: Staphylococcus aureus vaccine

BiOMViS has tested the potential of its OMV-based platform technology to develop a vaccine against Staphylococcus aureus.
S. aureus is a human pathogen responsible for community and hospital-acquired invasive diseases. In the USA, approximately 3.4 million community-acquired diseases and 340.000 hospital acquired-diseases occur annually, leading to more than 30.000 deaths.
To develop an anti-S. aureus vaccine, BiOMViS has selected five important S. aureus virulent factors and has expressed them in its OMV-producing strains. The antigens accumulate in the vesicular compartment at a concentration ranging from 5 to 20% of total OMV proteins. Importantly, engineered OMVs elicit high, saturating antigen-specific antibody titers in quantities as low as 0.2 μg/dose and mice from S. aureus challenge using different infection models. Such remarkable protection is obtained thanks to the synergistic activity of antigen-specific adaptive immunity and OMV-mediated T cell-independent immune responses.
BiOMViS is currently working on the optimization of the vaccine using different antigen combinations and is willing to negotiate with external partners interested to bring an OMV-based S. aureus vaccine to the clinics.